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Current Status of Hepatitis E Virus Infection in Korea
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Korea
Hepatitis E virus (HEV) is an emerging pathogen associated 
with acute viral hepatitis, and HEV is becoming increas-
ingly recognized. Approximately 2% of acute viral hepatitis 
is caused by HEV, and 18 cases of hepatitis E have been 
reported in Korea. Of these cases, only two have involved a 
history of travel from India, which suggests that they were 
imported cases. The remaining reported cases include a 
sporadic case of acute hepatitis E with genotype 4 HEV iso-
lates and identiﬁ  cation of the full genome sequence, as well 
as another case of genotype 4 HEV hepatitis that developed 
after ingestion of the raw bile juice of a wild bear living on 
a mountain in southern Korea. Moreover, genotype 3 HEV, 
which shows close genetic homology with swine HEV in Ko-
rea, has been detected in collected human serum samples. 
Therefore, genotypes 3 and 4 HEV are currently circulating 
in the Korean community and may be related to zoonotic 
transmission and food-borne infection. The reported anti-
HEV seroprevalence of 17% to 27% in the Korean popula-
tion suggests that HEV infection has been autochthonously 
circulating, thereby resulting in subclinical infection in Korea. 
Given the discrepancies among anti-HEV assays, the diag-
nosis of hepatitis E should be made with caution using ad-
equate antibody assays, and HEV RNA should be preferably 
detected from the stool. Further virological characterization 
and epidemiological study of the virus are warranted. (Gut 
Liver 2011;5:427-431)
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INTRODUCTION
Hepatitis E virus (HEV) is a nonenveloped, single stranded, 
positive sense RNA virus classified as Hepeviridae family, Hep-
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evirus genus, and an emerging pathogen of acute viral hepatitis 
with increasing recognition of the virus.
1 The epidemiology of 
HEV infection can be divided into 2 patterns: outbreak pattern 
in areas of high endemicity, mostly via water-borne or fecal-to-
oral transmission, and a sporadic pattern worldwide, mostly via 
zoonotic transmission and food borne transmission.
2 Clinical 
features are mostly indicative of typical acute hepatitis; howev-
er, it can show progression to chronic hepatitis or liver cirrhosis 
in immunocompromized hosts.
3 Specific treatments are lacking 
and therapy is supportive.
Although several cases of imported and autochthonous hepa-
titis E have been reported in Korea, the virological character-
ization of HEV in these case series had not been documented. 
Seroprevalence data reported in a few studies suggests that HEV 
has been circulating for a long time in the Korean community;
4 
however, it has been underdiagnosed due to underrecognition 
of the disease, and limited availability of diagnostic tools. This 
review will contain a brief overview of HEV infection and the 
current status of HEV infection in Korea.
HEV
The HEV genome is approximately 7.2 kb long with three 
open reading frames (ORF). ORF1 and 3 encode nonstructural 
proteins contributing to HEV replication and pathogenesis, 
whereas ORF 2 encodes the viral structural protein, capsid, 
which is the target for specific immune response.
1 According to 
the results of in vitro studies using HEV-like particles, the capsid 
protein contains receptor-binding domains and neutralizing epi-
topes.
2 HEV has a single serotype, but is further classified into 
four major genotypes, including genotype 1 (Burma), 2 (Mexico), 
3 (USA), and 4 (China), indicated as the originally identified 
viral isolates, while the most widely distributed type is genotype 
3.
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strains showed a different folding pattern of the capsid protein 
from that of genotype 1 strains.
6 
EPIDEMIOLOGY OF HEV INFECTION
Global distribution of HEV infection follows socioeconomic 
status. Highly endemic areas with higher than 20% anti-HEV 
prevalence include Central and South East Asia, including India, 
Malaysia, and China, as well as North Africa and the Middle 
East, including Egypt and Saudi Arabia. In low endemic areas, 
swine and human HEV strains show extremely close genetic 
relatedness, and special populations, including veterinarians, 
butchers, persons handling animal meat, and consumers of 
undercooked swine or wild deer meat have shown significantly 
higher seroprevalence than members of the general popula-
tion.
2,5,7 These findings indicate zoonotic transmission of HEV. 
Therefore, the epidemiology of HEV infection can be divided 
into 2 patterns: outbreak pattern and sporadic pattern. The out-
break pattern occurs primarily in highly endemic areas, where 
large epidemic episodes are intervening in the continuous en-
demicity, mostly via water-borne or fecal-to-oral transmission 
among human reservoirs. The sporadic pattern occurs world-
wide, mostly via zoonotic transmission and food borne trans-
mission.
7 In addition, parenteral transmission via blood transfu-
sion, organ transplantation, or mother-to child transmission has 
been described.
8
CLINICAL MANIFESTATIONS OF HEPATITIS E INFECTION
Clinical features of HEV infection range from asymptomatic 
hepatitis to severe, fulminant hepatitis, which can result in liver-
related mortality. Typical symptoms include fever, nausea, vom-
iting, general weakness, and jaundice lasting for 1 to 6 weeks 
after an incubation period of 2 to 6 weeks.
1 Hepatitis E superin-
fection with underlying stable chronic liver disease can present 
as acute hepatic decompensation. However, presence of immu-
noglobulin G (IgG) anti-HEV in patients with chronic liver dis-
ease did not differ from that of healthy blood donors. Moreover, 
previous exposure to HEV did not result in different outcomes 
among patients with chronic liver diseases.
9 HEV causes self-
limited, acute hepatitis in immunocompetent hosts. However, 
persistent HEV infection accompanied by chronic hepatitis and 
liver cirrhosis has been documented in immunocompromised 
hosts, such as organ transplantation recipients (liver, kidney, or 
pancreas) and HIV infected patients.
3,10
Hepatitis E in pregnancy has been reported to result in signif-
icantly higher mortality than in nonpregant women, especially 
in India or Parkistan, where genotype 1 and 2 HEV are preva-
lent. Patra et al.
11 reported that HEV infected icteric, pregnant 
women showed a significantly higher rate of fulminant hepatitis 
(55%), maternal mortality (41%), poorer fetal outcome (79%), 
and lower live birth (21%) than those of icteric, pregnant wom-
en with nonHEV acute viral hepatitis (20%, 7%, 51%, and 49%, 
respectively). The mechanism of severe outcomes of HEV infec-
tion in pregnancy has not been elucidated; however, pregnancy 
induced suppression of T cell immunity and T helper 2 (Th2) 
skewed cytokine patterns as well as increased viral load may 
be related to poor outcomes.
12 However, HEV infected pregnant 
women in the other endemic area of Egypt, where genotype 
3 is prevalent, did not show different outcomes from those of 
non-pregnant women. Moreover, no difference in outcome was 
observed between pregnant and nonpregnant animals in experi-
mentally infected animals. Further study of the mechanism of 
pathogenesis during pregnancy is warranted.
12
DIAGNOSIS OF HEPATITIS E
Diagnosis of hepatitis E was made by observance of typical 
symptoms with elevated aminotransferases, presence of IgM 
anti-HEV, and rising titer of IgG anti-HEV in exclusion of other 
etiology of acute hepatitis. Although positive detection of HEV 
RNA in serum or stool is a confirmatory diagnostic test, there is 
no commercially available HEV RNA detection assay. Enzyme 
immunoassays (EIA) for HEV antibodies are based on detec-
tion of antibodies against the highly conserved capsid protein. 
Immunoglobulin M (IgM) anti-HEV appears during the early 
stage of infection, and is detectable at 1 to 3 weeks after acute 
infection of immune-competent patients, while seroconversion 
may be delayed up to 6 to 10 months in immunocompromised 
patients. 
There are several anti-HEV assays; however, the performance 
of each anti-HEV assay has not been well studied. Mast et al.
13 
reported highly discrepant results among the different assays, 
which suggested that diagnosis of HEV infection using anti-
HEV tests should be made with caution. Genelabs anti-HEV EIA 
(Genelabs Diagnostics Pte. Ltd., Singapore), the most popular 
assay, showed good sensitivity (86.7%) for assay of IgG anti-
HEV, but less satisfactory sensitivity (53.3%) for IgM anti-HEV 
EIA for diagnosis of acute hepatitis E confirmed by positive 
detection of HEV RNA.
14 Findings from a recent study for com-
parison of 2 commercially available IgG anti-HEV kits (Genelabs 
EIA, and Wantai EIA [Wantai Biological Pharmacy Enterprise 
Co., Ltd., Beijing, China]) showed that Wantai EIA was more 
sensitive than Genelabs EIA, and remained positive for a longer 
time post infection.
15 
Detection of HEV RNA in serum or stool using nested or real-
time PCR is the most sensitive and definitive diagnostic test; 
however, the viremic period is short (10 to 30 days after onset 
of symptoms) and detection of HEV RNA within the proper time 
for diagnosis in the clinical setting is not easy, while fecal shed-
ding of virus may last longer with high viral titer compared to 
viremia in the blood.
16 Although there is no commercially avail-
able HEV RNA PCR assay, diagnosis of hepatitis E should be 
made with repeated use of anti-HEV (both of IgM and IgG) and Jeong SH: Hepatitis E in Korea  429
preferably detection of HEV RNA in stool or blood.
HUMAN CASES OF HEPATITIS E IN KOREA
Eighteen cases of hepatitis E have been reported in Korea; 
these cases are summarized in Table 1.
17-23 Among them, only 2 
cases involved a history of travel from India, suggesting import-
ed cases, and the remaining 16 cases had no history of travel 
from highly endemic areas. A sporadic case of acute hepatitis 
E with genotype 4 HEV isolates with identification of the full 
genome sequence in a middle aged woman was reported.
22 An-
other case of genotype 4 HEV hepatitis, which developed after 
ingestion of raw bile juice of a wild boar living on a mountain 
in southern Korea has recently been published, which suggests 
zoonotic transmission of HEV from a wild boar to a human in 
Korea.
23 A few studies have reported on detection of genotype 
3 HEV in collected sera from several diagnostic laboratories 
in Korea, which was similar to the genotype identified in pigs 
in Korea.
4,24 This suggests zoonotic transmission of HEV from 
pigs to humans in Korea; however, direct documentation of the 
transmission was not reported. 
In a recent study of the etiology of acute viral hepatitis in 
Korea, among 771 patients with acute viral hepatitis, 2% were 
attributable to HEV, while 77% were to hepatitis A virus, 4% to 
hepatitis B virus, 3% to hepatitis C virus, and 8% other viruses 
or cryptogenic causes.
25 Six percent of the patients showed posi-
tive results for both IgM anti-HEV and IgM anti-hepatitis A 
virus (HAV), which was a peculiar finding. According to clinical, 
serological, and molecular comparative analyses, coexistence of 
both IgM anti-HEV and IgM anti-HAV was a false positive result 
of IgM anti-HEV measured by Genelabs HEV IgM EIA (Genel-
abs Diagnostics Pte. Ltd.) in the setting of hepatitis A, rather 
than true coinfection of HAV and HEV. Of particular interest, 
IgM anti-HEV measured by Wantai IgM EIA (Wantai Biological 
Pharmacy Enterprise Co., Ltd.) did not show such false positive 
results, which suggests its advantage for use in diagnosis of 
hepatitis E infection in the Korean population, where genotype 3 
and 4 HEV circulate in the community (submitted paper). 
SEROPREVALENCE OF HEV INFECTION IN KOREA 
The IgG anti-HEV positive rate measured using Genelabs ELI-
Table 1. Summary of Reported Human Cases of Hepatitis E in Korea
Age, yr
/Sex
Symptom/
Travel history
ALT, IU/L
/Bilirubin, 
mg/dL
Clinical 
outcome
IgM 
anti-HEV
(titer/cutoff)
IgG 
anti-HEV 
(titer/cutoff)
HEV RNA Reference
27/M Fever, myalgia/No 6,200/6.8 Recovery Positive 
(1.22/0.45)
Positive  Not detected Korean J Hepatol (2002)
28/F Fever, diarrhea/India 1,776/1.7 Recovery Positive 
(1.77/0.44)
Positive 
(4.0/0.58)
Not detected Korean J Gastroenterol (2004)
34/F Jaundice/No 2,330/7.9 Recovery Positive 
(1.30/0.46)
Positive 
(1.27/0.62)
Not detected Korean J Gastroenterol (2006)
42/M Abdominal pain/No 690/10.6 Recovery Positive 
(1.10/0.43)
Positive 
(3.35/0.53)
Not detected Korean J Gastroenterol (2006)
30/M Fatigue/No 2,492/3.3 Recovery Positive Negative Not detected Korean J Hepatol (2006)
25/F Jaundice, fatigue/No 2,603/7.6 Recovery Positive Negative Not detected Korean J Gastroenterol (2006)
24/M Jaundice/India 1,147/10.3 Recovery Positive Positive Not detected Korean J Gastroenterol (2006)
29/M Jaundice/No 3,951/5.2 Recovery Positive Negative Not detected Korean J Gastroenterol (2006)
52/F Jaundice/No 789/6.8 Recovery Positive Negative Not detected Korean J Gastroenterol (2006)
45/M Fatigue/No 668/1.6 Recovery Positive Negative Not detected Korean J Gastroenterol (2006)
48/F Jaundice/No 1,582/11.2 Recovery Positive Negative Not detected Korean J Gastroenterol (2006)
42/F Jaundice/No 936/7.3 Recovery Positive Negative Not detected Korean J Gastroenterol (2006)
23/F Jaundice/No (underlying 
  autoimmune hepatitis)
121/40.9 Liver 
transplantation 
Positive Negative Not detected Korean J Gastroenterol (2006)
42/F Fever/No 216/1.0 Recovery Positive Not detected Not detected Korean J Gastroenterol (2007)
33/M Fatigue/No 316/9.5 Recovery Positive Not detected Not detected Korean J Gastroenterol (2007)
40/F Fatigue/No 236/0.5 Recovery Positive Not detected Not detected Korean J Gastroenterol (2007)
51/F Jaundice/No 2,643/2.2 Recovery Positive Positive Detected, 
genotype 4
Arch Virol (2010)
54/M Jaundice/No (ingestion of 
  raw bile juice of wild boar)
1,328/4.7 Recovery Positive
(3.62/0.30)
Positive
(3.73/0.38)      
Detected, 
genotype 4
J Clin Virol (2011)
HEV, hepatitis E virus.430  Gut and Liver, Vol. 5, No. 4, December 2011
SA has been reported as 17.7% in 96 serum samples from blood 
donors collected in 1995, and 11.9% in 361 serum samples 
collected from several diagnostic laboratories in medical health 
promotion centers.
4,24 Comparison of seroprevalence of HEV in 
adults older than 40 years in China, Korea, and Japan showed 
the highest rate (50.7%) in China, 34% in Korea, and 6% in 
Japan, which was measured using the Japanese EIA kit.
26 In de-
veloped countries, reported HEV data on seroprevalence range 
from 0.26% to 31%. Although seroprevalence reflects previous 
exposure to HEV infection, detection methods or assays for 
anti-HEV IgG vary in their performance, and comparison of 
seroprevalence among different populations is meaningful only 
when using a properly validated detection method. A recent 
comparative study of the performance of 2 commercial assays 
(Genelabs and Wantai HEV IgG EIA kits) showed that HEV se-
roprevalence data using the Genelabs assay had underestimated 
the true figure, compared with the Wantai assay, which was 
positive in more sera from proven cases, and remained positive 
for a longer time post infection.
15 
In the meantime, anti-HEV prevalence in pigs in Korea has 
been reported as 14.8%, and HEV RNA positivity among pigs 
has been reported as 2.3% to 10.8%, which showed genetic 
homology with swine and human HEV isolates in the United 
States and Japan (92.5% to 97%), and phylogenetic tree analysis 
indicated genotype 3.
24,27 A recent study reported an HEV RNA 
detection rate of 55% in pigs from an isolated region of Korea, 
Jeju island.
28 In addition, HEV RNA was detected in live oysters 
collected in various areas of Korea (14/161 samples, 8.7%),
29,30 
and was confirmed as genotype 3. 
TREATMENT AND VACCINES FOR HEPATITIS E
There is no specific antiviral therapy for hepatitis E, and sup-
portive care is the main therapy. However, specific antiviral 
treatment is required in severe or persistent hepatitis in immu-
nocompromised hosts. Kamar et al.
30 reported that pegylated in-
terferon could induce sustained virological response in the post-
transplantation setting. 
To date, 2 types of HEV vaccine have been developed. The 
first vaccine produced by GlaxoSmithKline is a genotype 1 
recombinant HEV protein vaccine prepared by a recombinant 
baculovirus system containing capsid antigen with aluminium 
hydroxide as an adjuvant; the vaccine efficacy was reported as 
95.5% after three doses in a phase 2 clinical trial including 5,323 
members of the Nepalese Army and the U.S. Army.
31 The second 
HEV vaccine (HEV239, Hecolin), which is a genotype 1 recom-
binant HEV capsid protein vaccine prepared by a recombinant 
E. coli system and adsorbed with aluminium hydroxide, was 
developed by Xiamen Innovax Biotech in China; the vaccine 
efficacy after 3 doses was reported as 100% in a phase 3 trial 
including 11,165 Chinese participants.
32 Travelers from areas 
of low-endemicity to highly endemic areas should be protected 
from HEV infection using the above vaccines. Although univer-
sal vaccination of children in highly endemic areas would be 
highly effective, specific programs or strategies for HEV vacci-
nation should be developed. 
CONCLUSIONS
HEV is a rare cause of acute viral hepatitis in Korea, which 
has shown a sporadic, nonendemic epidemiological pattern. 
Clinical features of hepatitis E appear to be relatively mild, 
compared to hepatitis A, and the viremic period in human cases 
appears to be short, which causes difficulty in detection of HEV 
RNA in serum samples. Genotype 3 and 4 HEV are circulat-
ing in Korean communities, which may be related to zoonotic 
transmission and food-borne infection. Seroprevalence of 17% 
to 27% suggests that HEV infection has been autochthonously 
circulating in Korea with commonly subclinical infection. Diag-
nosis of hepatitis E should be made with caution using adequate 
antibody assays and detection of HEV RNA, preferably in stool. 
Further study of the epidemiology and virologic characteriza-
tion of HEV is warranted.
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